Nasus Pharma Stock Hits 52-Week Low - Here's Why
Nasus Pharma Ltd. (AMEX:NSRX) shares are tumbling on Monday.The company announced topline results from its Phase 2 study of NS002, an investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis (severe allergic reaction), during the premarket session.Soon after the data, the stock price surged as high as $7.29 before falling.Nasus Pharma Candidate Works Faster Than EpiPenThe results demonstrated that NS002 has the potential to exceed EpiPen performance.The analysis showed statistically significant improvements in time to therapeutic threshold (T100) and in the proportion of subjects reaching the therapeutic epinephrine threshold within the first minutes following administration.The Phase 2 study showed that NS002 achieved significantly faster time to the critical 100 pg/mL epinephrine threshold compared to the widely used EpiPen, ...Full story available on Benzinga.com
